79
Participants
Start Date
November 19, 2019
Primary Completion Date
November 28, 2023
Study Completion Date
November 28, 2023
PF-07062119
PF-07062119
Anti-PD1
Anti-PD1 PF-06801591
Anti-VEGF
Anti-VEGF IV (bevacizumab)
Peter MacCallum Cancer Centre, Melbourne
The Royal Melbourne Hospital, Parkville
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion, New York
Evelyn H. Lauder Breast and Imaging Center, New York
Memorial Sloan Kettering Cancer Center - Main Campus, New York
University Hospitals Cleveland Medical Center, Cleveland
START Midwest, Grand Rapids
University of Texas MD Anderson Cancer Center, Houston
Christus Santa Rosa Hospital, San Antonio
NEXT Oncology, San Antonio
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora
UCLA Department of Medicine: Hematology-Oncology, Los Angeles
UCLA Hematology Oncology - Santa Monica, Santa Monica
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
City of Hope IDS Pharmacy, Duarte
National Cancer Center Hospital East, Kashiwa
National Cancer Center Hospital, Chuo-ku
Lead Sponsor
Pfizer
INDUSTRY